Prognostic Features in Patients with Metastatic Neuroendocrine Tumor Undergoing Y-90 Embolization
#307
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.
Aim(s): To determine the prognostic features associated with poorer survival in NET patients undergoing Y90 embolization.
Materials and methods: We performed a retrospective review of 110 patients with metastatic NETs who received Y90 embolization between 2004-2010. Kaplan-Meier methods were used. Biomarker responses were calculated within six months of the procedure. Cox Proportional-Hazard Models were then constructed to control for additional variables.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Soltman S, Amin S, Warner R, Weintraub J, Itzkowitz S,
Keywords: neuroendocrine, tumor, biomarker, embolization,
To read the full abstract, please log into your ENETS Member account.